Immunic Enrolls First Patient in Phase 2 Trial for Post COVID Syndrome

NEW YORK, September 4, 2024 – Immunic, Inc. (Nasdaq: IMUX) announced the enrollment of the first patient in a phase 2 clinical trial of vidofludimus calcium for Post COVID Syndrome (PCS). This trial, named RAPID_REVIVE, is sponsored by Goethe University Frankfurt and funded by the German government.

Vidofludimus calcium, Immunic's lead asset, is known for its antiviral and anti-inflammatory effects. The trial includes significant readouts on Epstein-Barr virus (EBV) reactivation, linked to fatigue, a common symptom in PCS and multiple sclerosis (MS) patients. Earlier studies showed the drug's potential in reducing fatigue in these conditions.

The RAPID_REVIVE trial will enroll 376 patients across 11 sites in Germany, with primary endpoints measuring physical function changes. Secondary endpoints will focus on mental and physical health, fatigue intensity, and cognitive function. Vidofludimus calcium aims to address these symptoms, providing hope for improved quality of life in PCS and MS patients.